Famed boot manufacturer Dr. Martens anticipates a significant financial setback due to US tariffs this year. The company, known for its iconic footwear, primarily manufactures its products in Vietnam, which has been affected by increased import duties as a result of the trade conflict initiated by President Donald Trump. Dr. Martens foresees a negative impact in the “high single digit” million-pound range on its annual profits due to these tariffs.
To mitigate the impact of higher tariffs, the company has already transitioned its production away from China, which formerly contributed to half of its manufacturing operations, in order to benefit from lower US import tariffs. Despite the tariff challenges, Dr. Martens remains confident in achieving its full-year profit forecast range of £53 million to £60 million before tax. However, this projection does not factor in the expected tariff-related losses.
The announcement regarding tariffs caused a sharp decline in the company’s stock price, dropping over 10% during early trading on Thursday. Dr. Martens, renowned for its classic yellow-stitched boots, has outlined plans to fully counterbalance the additional tariff expenses starting from the following year onwards. The company emphasized its commitment to achieving this goal through stringent cost management, adaptable product sourcing, and strategic adjustments to its pricing strategy in the USA.
In its recent update on tariffs, Dr. Martens also disclosed that it had reduced its losses to £11 million for the six months ending on September 28, compared to £12.3 million from the previous year. Additionally, sales saw a modest increase of 0.8% to £327.3 million in the first half of the fiscal year.
Ije Nwokorie, the CEO of Dr. Martens, highlighted the brand’s strength by pointing out a 33% rise in shoe volumes and successful product launches such as the Zebzag Laceless boot and the 1460 Rain boot. Despite market uncertainties and consumer caution, Nwokorie expressed confidence in the company’s strategies for the upcoming year.
Commenting on the company’s performance, Russ Mould, investment director at broker AJ Bell, acknowledged Dr. Martens’ gradual progress towards profitability. While the company’s recovery process is in motion, Mould suggested that the journey back to stability may be gradual rather than immediate. He noted positive signs in the half-year results, including increased full-price product sales, narrowed losses, and improved performance in the Americas region, which had previously posed challenges for the company.
However, investor response to the financial figures was subdued, as indicated by a decline in the share price during early trading, reflecting some disappointment in the market.